Department of Food Science and Technology, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Department of Food Science, Technology and Engineering Faculty of Agricultural Engineering and Technology, University of Tehran, Tehran, Iran.
Probiotics Antimicrob Proteins. 2019 Dec;11(4):1195-1201. doi: 10.1007/s12602-018-9468-x.
To the best of our knowledge, this study is the first evaluating the effects of probiotic honey intake on glycemic control, lipid profiles, biomarkers of inflammation, and oxidative stress in patients with diabetic nephropathy (DN). This investigation was conducted to evaluate the effects of probiotic honey intake on metabolic status in patients with DN. This randomized, double-blind, controlled clinical trial was performed among 60 patients with DN. Patients were randomly allocated into two groups to receive either 25 g/day probiotic honey containing a viable and heat-resistant probiotic Bacillus coagulans T11 (IBRC-M10791) (10 CFU/g) or 25 g/day control honey (n = 30 each group) for 12 weeks. Fasting blood samples were taken at baseline and 12 weeks after supplementation to quantify glycemic status, lipid concentrations, biomarkers of inflammation, and oxidative stress. After 12 weeks of intervention, patients who received probiotic honey compared with the control honey had significantly decreased serum insulin levels (- 1.2 ± 1.8 vs. - 0.1 ± 1.3 μIU/mL, P = 0.004) and homeostasis model of assessment-estimated insulin resistance (- 0.5 ± 0.6 vs. 0.003 ± 0.4, P = 0.002) and significantly improved quantitative insulin sensitivity check index (+ 0.005 ± 0.009 vs. - 0.0007 ± 0.005, P = 0.004). Additionally, compared with the control honey, probiotic honey intake has resulted in a significant reduction in total-/HDL-cholesterol (- 0.2 ± 0.5 vs. + 0.1 ± 0.1, P = 0.04). Probiotic honey intake significantly reduced serum high-sensitivity C-reactive protein (hs-CRP) (- 1.9 ± 2.4 vs. - 0.2 ± 2.7 mg/L, P = 0.01) and plasma malondialdehyde (MDA) levels (- 0.1 ± 0.6 vs. + 0.6 ± 1.0 μmol/L, P = 0.002) compared with the control honey. Probiotic honey intake had no significant effects on other metabolic profiles compared with the control honey. Overall, findings from the current study demonstrated that probiotic honey consumption for 12 weeks among DN patients had beneficial effects on insulin metabolism, total-/HDL-cholesterol, serum hs-CRP, and plasma MDA levels, but did not affect other metabolic profiles. http://www.irct.ir: IRCT201705035623N115.
据我们所知，这项研究是首次评估益生菌蜂蜜摄入对糖尿病肾病 (DN) 患者血糖控制、血脂谱、炎症生物标志物和氧化应激的影响。本研究旨在评估益生菌蜂蜜摄入对 DN 患者代谢状态的影响。这是一项随机、双盲、对照临床试验，共纳入 60 例 DN 患者。患者随机分为两组，分别每天摄入 25g 含有活菌和耐热益生菌凝结芽孢杆菌 T11（IBRC-M10791）（10CFU/g）的益生菌蜂蜜（n=30）或 25g 对照蜂蜜（n=30），持续 12 周。在基线和补充 12 周后采集空腹血样，以定量血糖状态、脂质浓度、炎症生物标志物和氧化应激。干预 12 周后，与对照组相比，摄入益生菌蜂蜜的患者血清胰岛素水平（-1.2±1.8 与-0.1±1.3μIU/mL，P=0.004）和稳态模型评估的胰岛素抵抗（-0.5±0.6 与 0.003±0.4，P=0.002）显著降低，定量胰岛素敏感性检查指数（+0.005±0.009 与-0.0007±0.005，P=0.004）显著改善。此外，与对照组相比，摄入益生菌蜂蜜可显著降低总胆固醇/高密度脂蛋白胆固醇（-0.2±0.5 与+0.1±0.1，P=0.04）。摄入益生菌蜂蜜可显著降低血清高敏 C 反应蛋白（hs-CRP）（-1.9±2.4 与-0.2±2.7mg/L，P=0.01）和血浆丙二醛（MDA）水平（-0.1±0.6 与+0.6±1.0μmol/L，P=0.002）。与对照组相比，摄入益生菌蜂蜜对其他代谢特征无显著影响。总的来说，本研究结果表明，DN 患者摄入益生菌蜂蜜 12 周对胰岛素代谢、总胆固醇/高密度脂蛋白胆固醇、血清 hs-CRP 和血浆 MDA 水平有有益影响，但对其他代谢特征没有影响。http://www.irct.ir: IRCT201705035623N115.
